Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. INCRELEX
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

INCRELEX

Medicine - Posted on Jul 17 2020
Active substance (DCI)
  • mécasermine
history (4)
  • 7/8/20

    INCRELEX (mécasermine)

    Modifications de l’AMM. Avis favorable au maintien du remboursement dans le traitement des retards de croissance chez l’enfa...
    icône flèche
  • 5/3/17

    INCRELEX (mecasermin), somatropin

    Minor clinical added value in the management of growth delays related to a severe primary IGF-1 deficiency INCRELEX (recombi...
    CAV :
    54321
    icône flèche
  • 6/22/11

    INCRELEX

    Pas d’avantage clinique pour le traitement du déficit en IGF-1 INCRELEX est indiqué dans le traitement à long terme des reta...
    CAV :
    54321
    icône flèche
  • 12/5/07

    INCRELEX

    INCRELEX
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • H01AC03
Manufacturer
IPSEN PHARMA
Presentation

INCRELEX 10 mg/ml, solution injectable (code CIS : 66263258)
1 flacon(s) en verre de 4 ml (CIP : 34009 381 467 7 6)

All our publications
    Bone and cartilage diseases Congenital, genetic and rare diseases Drug therapy Endocrine system diseases Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mFFv2jAQx9/5FFEe9kYCpVC6JVQbazekVmO0aNNeKpMcxSzY6dkG2k8/h1CVTs66GvyYOPnf2Xf++S9HZ+tF5i0BBeUs9ptBw/eAJTyl7C72xzcX9a5/1qtFc7IkO5+dBI2geeR7SUaEiP1iNJgAYSL4eXX5GfT/gH6v5kV8ModEvvhOSZoFX4mYXZG8+MaLlpym3gLkjKexnyu5eetFQqLOorfi+FvkJIEo3L7ZHZ3fHu++j8JC7D9UlQC8JOzOKArMSjNRiMBkn0i44/hQkW/LSpuKEQiuMIEhkbMh8iVNITWGmJJMgFWQ6Sq9BlxmIIsgRvFwniyElTiZk/UI7gfmpD/q0b5cy3qj3jw57nQ7jUbrpH3UtQqFO0tlroKeRJjnmN4enXZbnVY3BBZSliBksLasz5CjJJmjylDRf9lcjuIg3L/aASkVeUYegrnIbZeKINHDgBoB7iZSzOAGNZQyvWZ/6TOVZeEbsx5vkeEo44JIfa6YrCDHxch2IfqcSVhXV9QOdnK97UUK4nCyj5yZQT9Uk4wmtljT4FEg5Hg0qKbaoYHwiQgYozsi/KAs5StxeNLsVtZR9vkGlkZRXYRmUYVOs9223ki/dBtVnDTnCnkOoWYQFfugZcCmfF+o6M40Sz315UFbcuN5eEIyqHA9dUvG6F58MmnOut3dTioHjKJfzm9sW+S7Any43jwapWka7xbXjsEuwK578rXcy90b57etRrt72jp+Rxb5hydHHVu651LUiXlWaEbNTMpcvA/D1WoVzIioC6LXM5jiv4+DM+P0D7EEmr3PFXXn8Z34gdIfldx1lPqkPFDfVkrb/fuaY9jXBW//37ptYwyJCvaoRYl6Z0AenB+e8c8W2FnawxeYcRdmY1eJpJy5slBqYobzvqeKLi27QM2Ib9Mprbh2qWzNKCyvfHq1KCyue3q1P70FCkM=
SaZ3cAgzpAYc6szU